OTC Markets Group Welcomes Abattis Bioceuticals to OTCQX®; EPIC Receives Symbol for Preferred Stock Print E-mail
By Staff and Wire Reports   
Friday, 11 July 2014 19:32
Below is a look at some of the headlines for companies that made news in the healthcare sector on July 11, 2014.
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced that Abattis Bioceuticals Corp. (CSE: ATT; OTCQX: ATTBF), a specialty biotechnology company, has qualified to trade on OTCQX®, the best marketplace.

Abattis begins trading today on OTCQX under the symbol "ATTBF."  U.S. investors can find current financial disclosures and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

"We welcome Abattis to the OTCQX marketplace," said R. Cromwell Coulson, President and CEO of OTC Markets Group.  "Abattis joins a growing group of Canadian exchange-listed companies that have chosen to trade on the OTCQX market to provide its investors with transparent trading and convenient access to its news and financials.  We wish the company continued success." 

"Abattis Bioceuticals is dedicated to providing a high level of transparency to shareholders," said Abattis Bioceuticals Corp. CEO Mike Withrow. "The upgrade to OTCQX provides investors with increased transparency in financial reporting and disclosure and awareness of the company's activities within the botanical drug and cannabis industry and inspires confidence within the investment community."

Troutman Sanders LLP serves as Abattis' Principal American Liaison ("PAL") on OTCQX, responsible for providing professional guidance on OTCQX requirements and U.S. federal securities laws.

Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal marijuana markets in North America.


EPIC Corporate (PINKSHEETS: EPOR) and Ronald S. Tucker, EPIC's president, announced "EPIC has received a symbol ("EPORP") for its Series A 5% Convertible Preferred Stock."

Shares of EPIC's common stock purchased up to and on July 15, 2014, can be exchanged, provide that the Notice of Acceptance is given to your broker/dealer before 5:00 pm (EST) July 15, 2014.

Preferred Shareholders, based on an average cost of $.25 per common share, receive an annual yield of 13.33% from the 5% dividend whether in cash or EPIC's common stock. By selling the stock receive from a stock dividend the yield could be higher.

Also Friday:

Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Doxylamine Succinate and Pyridoxine Hydrochloride Delayed-release tablets, 10 mg/10 mg. 

Affinor Growers (CSE:AFI) (FRANKFURT:1AF) (OTCQB:RSSFF) has signed a LOI to acquire all the assets of 0993341 "BC" Ltd related to the operation of the Vancouver rooftop growing facility, located at 523/535 Richards Street, subject to due diligence.

Align Technology, Inc. (NASDAQ: ALGN)
today announced that its 2013 consumer campaign, "Smile and the Whole World Smiles With You" received the Excellence in Integrated Digital Communication award at the 2014 Communique Awards on July 3.

Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX)
, a late clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, announced today the pricing of its underwritten public offering of 3,150,000 shares of common stock at a price to the public of $19.25 per share.

Entia Biosciences, Inc. (OTCQB: ERGO)
is excited to announce that its GROH brand will be an official sponsor of the 4th Annual, Battle of the Strands competition.

announces today that the Company, subject to all necessary regulatory approvals, has entered into shares for debt agreements with its Chief Executive Officer, Dr. Albert Friesen and certain members of the Board of Directors, pursuant to which the Company will issue 205,867 of its common shares at a deemed price of $1.98 per common share to satisfy $407,616.66 of outstanding amounts owing to Dr. Friesen and members of the Company's Board of Directors.

Rock Creek Pharmaceuticals, Inc. (NASDAQ: RCPI)
, an emerging biotechnology company, today announced that the Food and Drug Administration ("FDA"), has notified the Company that the agency will provide comments on RCP's Investigational New Drug ("IND") application before granting the Company permission to start its clinical trial in the US.

Verde Media Group Inc. (PINKSHEETS: VMGI)
, a provider of needle-free injectable devices and an emerging growth Biotechnology company, announces today that Chief Executive Officer (CEO) William Veve will be interviewed live by host Amilya Antonetti on ABC Talk Radio's "The Amilya Show," Saturday, July 12th at 1:30pm ET.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus